Pfizer (PFE.US) shares gained nearly 3.6% in early trading today after the drugmaker boosted its revenue and revised upward its full-year earnings per share forecast, citing strong demand for its Paxlovid formulation. The vaccine maker also reported third-quarter sales that exceeded analysts' estimates. Despite the strong results, the stock erased early gains and is currently losing 1.5%.
COMMENTS FROM WALL STREET ANALYSTS:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appJP Morgan - “(...) revenue growth in the quarter was largely driven by the sale of another sizable tranche of Covid vaccines. Ultimately, we believe that an improved performance in terms of new product launches and/or further progress in the development of current projects will be required for a significant change in the company's narrative, which we believe is more likely in the second half of FY25 or beyond.”
Barclays - “upward guidance revisions are mainly due to vaccines on Covid. “We expect an increased focus on momentum in 2025 (where the company has said little to date).”
ANNUAL FORECAST
- Adjusted earnings per share of $2.75 to $2.95, previously estimated at $2.45 to $2.65
- Revenue of $61.0 to $64.0 billion, previously estimated $59.5 to $62.5 billion
THIRD QUARTER RESULTS
- Revenues $17.70 billion, estimate $15.08 billion
- Research and development costs $2.56 billion, estimate $3.06 billion
OTHER COMMENTS:
- Current financial forecasts do not include any share repurchases in 2024
Financial dashboard with key financial information regarding the company. Source: XTB
The company's shares are losing nearly 1.5% in today's session and have broken out of the zone of local minima that has capped deeper declines since August of this year.
Source: xStation
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
